Company intelligence
HUTCHMED
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first three medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch‑med.com or follow us on LinkedIn.
Verified activity
Signals from HUTCHMED
3 published signals
Partnerships
HUTCHMED will host webcasts on Thursday September 3, 2026 at 4:30 p.m. HKT in Chinese (Putonghua) and at 7:30 a.m. EDT / 12:30 p.m. BST / 7:30 p.m. HKT in English.
Reported by HUTCHMED
Partnerships
HUTCHMED announced an exclusive global development and licensing agreement with GSK for HMPL-A830, a first-in-class Antibody-Targeted Therapy Conjugate combining a potent KRAS small molecule inhibitor payload with an anti-EGFR antibody.
Reported by HUTCHMED
Research & Knowledge
HUTCHMED announced positive high-level results from the SANOVO China Phase III trial in treatment-naïve patients with MET-overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC).
Reported by HUTCHMED